131 related articles for article (PubMed ID: 24925834)
1. Prostate-specific antigen density toward a better cutoff to identify better candidates for active surveillance.
Ha YS; Yu J; Salmasi AH; Patel N; Parihar J; Singer EA; Kim JH; Kwon TG; Kim WJ; Kim IY
Urology; 2014 Aug; 84(2):365-71. PubMed ID: 24925834
[TBL] [Abstract][Full Text] [Related]
2. Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?
Tsang CF; Lai TCT; Lam W; Ho BSH; Ng ATL; Ma WK; Yiu MK; Tsu JHL
Prostate Int; 2019 Jun; 7(2):73-77. PubMed ID: 31384609
[TBL] [Abstract][Full Text] [Related]
3. Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients.
Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
Eur Urol Oncol; 2018 Aug; 1(3):231-237. PubMed ID: 31102626
[TBL] [Abstract][Full Text] [Related]
4. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
5. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific Antigen Density Is a Good Predictor of Upstaging and Upgrading, According to the New Grading System: The Keys We Are Seeking May Be Already in Our Pocket.
Brassetti A; Lombardo R; Emiliozzi P; Cardi A; Antonio V; Antonio I; Aldo S; Tommaso R; Alberto P; Gianluca D
Urology; 2018 Jan; 111():129-135. PubMed ID: 29032238
[TBL] [Abstract][Full Text] [Related]
7. Primary Gleason pattern upgrading in contemporary patients with D'Amico low-risk prostate cancer: implications for future biomarkers and imaging modalities.
Leyh-Bannurah SR; Abou-Haidar H; Dell'Oglio P; Schiffmann J; Tian Z; Heinzer H; Huland H; Graefen M; Budäus L; Karakiewicz PI
BJU Int; 2017 May; 119(5):692-699. PubMed ID: 27367469
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
9. Should inclusion criteria for active surveillance for low-risk prostate cancer be more stringent? From an interim analysis of PRIAS-JAPAN.
Sugimoto M; Hirama H; Yamaguchi A; Koga H; Hashine K; Ninomiya I; Shinohara N; Maruyama S; Egawa S; Sasaki H; Kakehi Y;
World J Urol; 2015 Jul; 33(7):981-7. PubMed ID: 25428792
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
[TBL] [Abstract][Full Text] [Related]
11. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
12. Increased incidence of pathologically nonorgan confined prostate cancer in African-American men eligible for active surveillance.
Ha YS; Salmasi A; Karellas M; Singer EA; Kim JH; Han M; Partin AW; Kim WJ; Lee DH; Kim IY
Urology; 2013 Apr; 81(4):831-5. PubMed ID: 23465143
[TBL] [Abstract][Full Text] [Related]
13. Role of Multi-Parametric Magnetic Resonance Image and PIRADS Score in Patients with Prostate Cancer Eligible for Active Surveillance According PRIAS Criteria.
Almeida GL; Petralia G; Ferro M; Ribas CA; Detti S; Jereczek-Fossa BA; Matei DV; Coman I; De Cobelli O; Tagliabue E
Urol Int; 2016; 96(4):459-69. PubMed ID: 27045167
[TBL] [Abstract][Full Text] [Related]
14. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
15. Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS).
El Hajj A; Ploussard G; de la Taille A; Allory Y; Vordos D; Hoznek A; Abbou CC; Salomon L
BJU Int; 2013 Jan; 111(1):53-9. PubMed ID: 22726582
[TBL] [Abstract][Full Text] [Related]
16. Percentage of cancer involvement in positive cores can predict unfavorable disease in men with low-risk prostate cancer but eligible for the prostate cancer international: active surveillance criteria.
Russo GI; Cimino S; Castelli T; Favilla V; Urzì D; Veroux M; Madonia M; Morgia G
Urol Oncol; 2014 Apr; 32(3):291-6. PubMed ID: 24184119
[TBL] [Abstract][Full Text] [Related]
17. [The significance of PSA density as predictive factor in Afro-Caribbean patients eligible for active surveillance by the French protocol criteria].
Loiselle A; Senechal C; Nevoux P; Benazzouz H; Bhakkan-Mambir B; Casenave J; Gourtaud G; Fofana M; Blanchet P
Prog Urol; 2014 May; 24(6):327-33. PubMed ID: 24821554
[TBL] [Abstract][Full Text] [Related]
18. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
[TBL] [Abstract][Full Text] [Related]
19. Pathological findings following radical prostatectomy in patients who are candidates for active surveillance: impact of varying PSA levels.
Kang DI; Jang TL; Jeong J; Choi EY; Johnson K; Lee DH; Kim WJ; Kim IY
Asian J Androl; 2011 Nov; 13(6):838-41. PubMed ID: 21785442
[TBL] [Abstract][Full Text] [Related]
20. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
